Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (2,852,108)	$ (2,766,188)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense included in - General and administrative costs	157,659	775,124
Stock-based compensation expense included in - Research and development costs	392,038	171,049
Fair value of warrant - Extensions	34,016	302,691
Fair value of warrant - Discounts	171,757	$ 134,420
(Increase) decrease in -
Licensing fee receivable	(200,000)
Advances on research and development contract services	23,500	$ (197,297)
Prepaid expenses and other current assets	(10,910)	(7,006)
Increase (decrease) in -
Accounts payable and accrued expenses	36,542	14,760
Research and development contract liabilities	$ 66,380	10,903
Registration rights penalty obligation		(74,000)
Net cash used in operating activities	$ (2,181,126)	(1,635,544)
Cash flows from investing activities:
(Increase) decrease in money market funds	109,604	(207,564)
Net cash provided by (used in) investing activities	109,604	$ (207,564)
Cash flows from financing activities:
Proceeds from sale of Series A Convertible Preferred Stock	1,750,000
Cash payments made for costs incurred in connection with sale of Series A Convertible Preferred Stock	(12,608)
Proceeds from exercise of warrants	315,000	$ 1,412,500
Net cash provided by financing activities	2,052,392	1,412,500
Cash:
Net decrease	(19,130)	(430,608)
Balance at beginning of period	44,411	475,019
Balance at end of period	$ 25,281	$ 44,411
Supplemental disclosures of cash flow information:
Interest
Income taxes
Non-cash financing activities:
Conversion of advances due to Chairman and major stockholder into common stock	$ 92,717
Accrued dividend on Series A Convertible Preferred Stock	$ 2,000